Table 1 In vitro cytotoxicity of... | American Society of Hematology

Table 1

In vitro cytotoxicity of nAb-IFNα on hematopoietic tumor cell lines

Cell line	Type	HLA-DR expression, MFI	CD20 expression, MFI	C2-2b-2b			20-2b-2b			734-2b-2b		hL243γ4p		hL243γ4p + 734-2b-2b
Cell line	Type	HLA-DR expression, MFI	CD20 expression, MFI	IC₅₀, nM	TI, fold	I_max, %	IC₅₀, nM	TI, fold	I_max, %	IC₅₀, nM	I_max, %	IC₅₀, nM	I_max, %	IC₅₀, nM	I_max, %
Daudi	BL	2092*	500*	3 × 10⁻⁵	117	95	1 × 10⁻⁴	25	95	3 × 10⁻³	95	5.13	67	4 × 10⁻³	95
Raji	BL	2317*	391*	0.35	23	70	3.89	2	60	8.13	62	> 20†	45	0.56	70
Ramos	BL	373*	516*	0.90	> 20	82	7.76	> 3	70	> 20†	35	> 20†	25	> 20†	43
WSU-FSCCL	FL	2030*	37*	0.19	> 100	80	> 20†		22	> 20†	24	0.37	85	0.46	73
Jeko-1	MCL	539*	250*	0.10	> 200	100	1.1	> 20	59	> 20†	21	0.4	98	0.18	90
Granta-519	MCL	1797*	805*	4.0	> 5	66	> 20†		31	> 20†	14	6.4	59	3.5	66
CAG	MM	2804*	4*	3 × 10⁻³	55	98	0.13	1	85	0.16	85	20	52	0.08	98
NCI-H929	MM	4‡	1‡	0.13	1	98	0.14	1	98	0.11	98	> 20†	0	0.12	98
KMS12-PE	MM	940*	3*	0.63	6	80	3.28	1	72	3.9	68	> 20†	27	0.97	76
KMS12-BM	MM	1502*	318*	0.51	> 50	73	7.82	> 3	55	> 20†	22	3.47	59	0.61	73
MM1R	MM	79‡	1‡	2 × 10⁻³	10	100	0.05	0.5	95	0.02	97	> 20†	10	0.03	98
KMS11	MM	615*	3*	1.85	> 10	66	> 20†		21	> 20†	24	2.19	62	1.72	66
OPM6	MM	41‡	2‡	4 × 10⁻³	2	99	8 × 10⁻³	1	99	8 × 10⁻³	99	> 20†	6	8 × 10⁻³	99
U266	MM	223‡	2‡	9 × 10⁻⁴	22	96	0.02	1	93	0.02	92	> 20†	10	8 × 10⁻³	91
HC-1	HCL	5501*	1079*	0.08	134	91	0.47	23	69	10.72	59	0.59	89	0.49	89
Kasumi-3	AML	445*	5*	6 × 10⁻³	18	87	0.10	1	78	0.11	76	> 20†	0	0.09	81
GDM-1	AML	553*	4*	8	> 3	68	> 20†		11	> 20†	35	> 20†	0	> 20†	35
MEC-1	CLL	2421*	271*	1.2	17	78	20	> 1	50	> 20†	34	> 20†	30	20	50
WAC	CLL	799*	211*	2.19	> 10	79	> 20†		26	> 20†	20	> 20†	37	5.89	60
REH	ALL	2583*	15*	2.14	12	67	13.80	2	57	26.30	52	7.46	64	4.95	64
697	ALL	1108*	13*	> 20†		40	> 20†		40	> 20†	23	> 20†	18	> 20†	34
RS4/11	ALL	2522*	3*	> 20†		41	> 20†		39	> 20†	36	> 20†	19	> 20†	41

Cell line	Type	HLA-DR expression, MFI	CD20 expression, MFI	C2-2b-2b			20-2b-2b			734-2b-2b		hL243γ4p		hL243γ4p + 734-2b-2b
Cell line	Type	HLA-DR expression, MFI	CD20 expression, MFI	IC₅₀, nM	TI, fold	I_max, %	IC₅₀, nM	TI, fold	I_max, %	IC₅₀, nM	I_max, %	IC₅₀, nM	I_max, %	IC₅₀, nM	I_max, %
Daudi	BL	2092*	500*	3 × 10⁻⁵	117	95	1 × 10⁻⁴	25	95	3 × 10⁻³	95	5.13	67	4 × 10⁻³	95
Raji	BL	2317*	391*	0.35	23	70	3.89	2	60	8.13	62	> 20†	45	0.56	70
Ramos	BL	373*	516*	0.90	> 20	82	7.76	> 3	70	> 20†	35	> 20†	25	> 20†	43
WSU-FSCCL	FL	2030*	37*	0.19	> 100	80	> 20†		22	> 20†	24	0.37	85	0.46	73
Jeko-1	MCL	539*	250*	0.10	> 200	100	1.1	> 20	59	> 20†	21	0.4	98	0.18	90
Granta-519	MCL	1797*	805*	4.0	> 5	66	> 20†		31	> 20†	14	6.4	59	3.5	66
CAG	MM	2804*	4*	3 × 10⁻³	55	98	0.13	1	85	0.16	85	20	52	0.08	98
NCI-H929	MM	4‡	1‡	0.13	1	98	0.14	1	98	0.11	98	> 20†	0	0.12	98
KMS12-PE	MM	940*	3*	0.63	6	80	3.28	1	72	3.9	68	> 20†	27	0.97	76
KMS12-BM	MM	1502*	318*	0.51	> 50	73	7.82	> 3	55	> 20†	22	3.47	59	0.61	73
MM1R	MM	79‡	1‡	2 × 10⁻³	10	100	0.05	0.5	95	0.02	97	> 20†	10	0.03	98
KMS11	MM	615*	3*	1.85	> 10	66	> 20†		21	> 20†	24	2.19	62	1.72	66
OPM6	MM	41‡	2‡	4 × 10⁻³	2	99	8 × 10⁻³	1	99	8 × 10⁻³	99	> 20†	6	8 × 10⁻³	99
U266	MM	223‡	2‡	9 × 10⁻⁴	22	96	0.02	1	93	0.02	92	> 20†	10	8 × 10⁻³	91
HC-1	HCL	5501*	1079*	0.08	134	91	0.47	23	69	10.72	59	0.59	89	0.49	89
Kasumi-3	AML	445*	5*	6 × 10⁻³	18	87	0.10	1	78	0.11	76	> 20†	0	0.09	81
GDM-1	AML	553*	4*	8	> 3	68	> 20†		11	> 20†	35	> 20†	0	> 20†	35
MEC-1	CLL	2421*	271*	1.2	17	78	20	> 1	50	> 20†	34	> 20†	30	20	50
WAC	CLL	799*	211*	2.19	> 10	79	> 20†		26	> 20†	20	> 20†	37	5.89	60
REH	ALL	2583*	15*	2.14	12	67	13.80	2	57	26.30	52	7.46	64	4.95	64
697	ALL	1108*	13*	> 20†		40	> 20†		40	> 20†	23	> 20†	18	> 20†	34
RS4/11	ALL	2522*	3*	> 20†		41	> 20†		39	> 20†	36	> 20†	19	> 20†	41

Cultures were grown in 48-well plates until the density of untreated cells increased a minimum of 10-fold (3-7 days).

MFI indicates mean fluorescent intensity; IC₅₀, concentration (nM) resulting in 50% growth inhibition compared with untreated cells; TI, targeting index = fold reduction in EC₅₀ compared with nontargeted IFNα (734-2b-2b); I_max, maximal percentage decrease in viable cells compared with untreated cells; BL, Burkitt lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; HCL, hairy cell leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; and ALL, acute lymphoblastic leukemia.

Previously reported in Rossi et al.¹⁵

†

Treatment failed to reach 50% inhibition.

‡

Previously reported in Rossi et al.¹⁴

View Large

This Feature Is Available To Subscribers Only